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Abstract
Purpose: To evaluate the psychometric properties of the Patient-Reported Outcome
Measurement Information System® Fatigue Short Form 7a (PROMIS F-SF) among people with
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Methods: Analyses were conducted using data from the Multi-Site Clinical Assessment of
ME/CFS study, which recruited participants from seven ME/CFS specialty clinics across the US.
Baseline and follow-up data from ME/CFS participants and healthy controls were used.
Ceiling/Floor effects, internal consistency reliability, differential item functioning (DIF), knowngroups validity, and responsiveness were examined.
Results: The final sample comprised 549 ME/CFS participants at baseline, 386 of whom also
had follow-up. At baseline, the sample mean of PROMIS F-SF T-score was 68.6 (US general
population mean T-score of 50 and standard deviation of 10). The PROMIS F-SF demonstrated
good internal consistency reliability (Cronbach’s α = 0.84) and minimal floor/ceiling effects. No
DIF was detected by age or sex for any item. This instrument also showed good known-groups
validity with medium-to-large effect sizes (η2=0.08 to 0.69), with a monotonic increase of the
fatigue T-score across ME/CFS participant groups with low, medium, and high functional
impairment as measured by 3 different variables (p<0.01), and with significantly higher fatigue
T-scores among ME/CFS participants than healthy controls (p<0.0001). Acceptable
responsiveness was found with small-to-medium effect sizes (Guyatt's Responsiveness
Statistic=0.28 to 0.54).
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Conclusions: Study findings support the reliability and validity of PROMIS F-SF as a measure
of fatigue for ME/CFS and lend support to the drug development tool submission for qualifying
this measure to evaluate therapeutic effect in ME/CFS clinical trials.
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Introduction
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating long-term
illness [1,2]. ME/CFS affects multiple body systems and is characterized by at least six months
of reduced ability to perform usual activities, accompanied by incapacitating fatigue experienced
as profound exhaustion. Other symptoms include dizziness and problems with sleep,
concentration, and memory. A distinctive characteristic of the illness is post-exertional malaise,
which is a worsening of ME/CFS symptoms following physical or mental exertion that may
require an extended recovery period [3]. The consequences of ME/CFS are devastating for
individuals and their families and costly for society: those with moderate-to-severe disease are
mostly housebound and may have lost many of their social roles; while those with very severe
disease are mostly bedbound and cannot visit a provider for therapy [2]. Several populationbased studies estimated the prevalence of ME/CFS among the United States (US) population at
more than 1 million [4-6]. Costs associated with ME/CFS are estimated at $18–$51 billion
annually in the US ($9–$14 billion in medical costs and $9–$37 billion in lost productivity) with
about one-quarter of medical expenses paid directly out-of-pocket [7-9].
Despite the significant impact on individuals, families, and society, there still are no FDAapproved treatments for ME/CFS. Clinical research approved by FDA requires valid, fit-forpurpose assessments to document change due to intervention (e.g., when used as primary or
secondary endpoints); yet, such assessments for ME/CFS are not currently available. The variety
of research and clinical case definitions for ME/CFS [10-12,1] consistently recognize the
importance of fatigue to the experience of the illness. Thus, the use of a fatigue measure as a
drug development tool (DDT) for therapy for ME/CFS is important; yet, the choice of a fatigue
measure for ME/CFS is challenged by lack of consensus regarding how fatigue should be
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assessed for patients with ME/CFS. We sought to meet this challenge by leveraging recent
advances in the science of measuring symptoms of chronic illness.
The Patient Reported Outcome Measurement Information System® (PROMIS®) is the product of
a massive effort begun in 2004 and based on modern measurement theory, to address the need to
develop precise, consensus measures of health outcome, including fatigue, suitable for use across
chronic diseases. The PROMIS Fatigue Short Form 7a (PROMIS F-SF) is a seven-item
questionnaire derived from the 95-item PROMIS Fatigue item bank [13] that assesses both the
experience of fatigue and the interference of fatigue on daily activities over the past week [14].
Compared with other fatigue measures used in ME/CFS research, such as the Multidimensional
Fatigue Inventory [15] and the Chalder Fatigue Scale [16], the key advantage of the PROMIS FSF is its use of item response theory (IRT) to increase the precision and interpretability of scores
while reducing respondents’ burden. Specifically, IRT could improve the ability of scores to
discriminate between various levels of fatigue. Moreover, IRT produces standardized scores that
are readily comparable across different studies or patient populations, which help bring clinical
meaning to the fatigue score for ME/CFS patients. The PROMIS F-SF can achieve evaluations
of fatigue within a few minutes [17], which is particularly important to respondents with
extremely limited energy, such as ME/CFS patients. However, its psychometric properties when
used with ME/CFS patients, specifically, have not been documented. A concern about the use of
a fatigue assessment as a measure of outcome for ME/CFS is that given the nature of the disease,
there would be a restriction in the range of possible scores such that most patients would have
the highest fatigue score possible. This could lead to poor evidence of reliability and validity of
the scores.
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In the present study, we evaluated the psychometric properties of the PROMIS F-SF to describe
the fatigue of people suffering from ME/CFS using data from ME/CFS specialty clinics in the
US. We aimed to obtain information that could be used in an application to the FDA to qualify
the PROMIS F-SF as a DDT for use in clinical trials of therapy for ME/CFS. As described in
FDA’s guidance for clinical outcome assessment (COA) qualification[18], a patient-reported
outcome instrument needs to be evaluated within the intended patient population in terms of testretest reliability, internal consistency, content validity, construct validity (e.g., known-groups
validity), and responsiveness. The current study provided information on all the required
measurement properties except content validity and test-retest reliability.
Methods
Data Source and Study Sample
Data were obtained from the Multi-Site Clinical Assessment of Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome (MCAM) study [19]. The study was approved by
the Institutional Review Boards of the Centers for Disease Control and Prevention, Open
Medicine Institute Consortium, Mount Sinai Beth Israel, and Nova Southeastern University.
One of the objectives for the MCAM study was to improve how ME/CFS symptoms could be
measured. In brief, MCAM was conducted in multiple stages with a rolling cohort design. Not all
participants were enrolled in the same stage; therefore, baseline data could come from any stage.
Participants were recruited from seven ME/CFS specialty clinics across seven US states. The
MCAM study relied on ME/CFS expert clinicians to determine patient eligibility using their
clinical expertise with the condition. Enrolled patients were 18 to 70 years of age who had been
diagnosed with CFS, ME, or post-infectious fatigue or who were managed as were other
ME/CFS patients in the clinical practice.
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Of 549 participants who completed the baseline assessment, 386 also completed the follow-up
assessment approximately 10-to-14 months after baseline. Participants did not receive any
intervention between their baseline and follow-up assessments. We used the baseline data from
ME/CFS participants for most of the analyses, and data from participants who completed both
baseline and follow-up assessments for evaluating responsiveness of the PROMIS F-SF over
time. In addition, we used data from 304 healthy controls to examine known-groups validity.
Measures
PROMIS F-SF: The PROMIS F-SF was one of the instruments administered to participants of
the MCAM study, via web-based platforms at five clinics and paper forms at the other two
clinics. Prior research showed PROMIS scores to be robust to mode effects in comparisons of
electronic to paper and pencil modes [20]. PROMIS F-SF includes seven items with response
options on a 5-point Likert scale, ranging from 1 = “never” to 5 = “always.” One item, “How
often did you have enough energy to exercise strenuously,” is reverse scored so that higher
scores indicate greater fatigue. The PROMIS fatigue item bank was developed using a mixedmethod approach and IRT methods [21]. Scores were on a T-score metric (mean=50, standard
deviation, SD=10), so that one can compare the score to the national norm (e.g., 50 referred as
the mean T-score of the US general population), matching the marginal distributions of gender,
age, race, and education in the 2000 US Census [22].
In the validity analysis, we also included the following patient characteristics: Hours spent in
vertical/horizontal activities per day, and physical health as measured by the SF-36 Health
Survey (SF-36). We considered these three variables as proxy measures of functional impairment
due to ME/CFS and used them to define groups of participants when evaluating known-groups
validity. Data for these survey questions were collected at the same time as data for the PROMIS
7

F-SF. The information for age and sex was abstracted from medical records and used in the
differential item functioning (DIF) analysis.
Analyses
All IRT analyses were conducted using the IRTPRO software Version 4.2 [23] and other
analyses using SAS 9.4 [24].
Descriptive Statistics. ME/CFS patients often experience unusual fatigue that the general
population does not experience. Therefore, generic fatigue measures might be more likely than
condition-specific measures to have a restricted range of measurement among ME/CFS patients.
In other words, ME/CFS patients may be more likely than patients with other chronic conditions,
to select the response option that indicates the greatest fatigue for all items in the measure. For
each item from the PROMIS F-SF, we calculated univariate descriptive statistics including the
mean, standard deviation, and frequency distribution. In addition, we examined the proportion of
ME/CFS participants at the lowest or highest possible score for the entire measure. We adopted a
standard of less than 15% of respondents at either the highest or lowest fatigue score as our
standard for evaluating the suitability of the PROMIS F-SF for ME/CFS [25,26].
IRT Scoring. We applied IRT models to score the PROMIS F-SF. T-scores were calculated for
both ME/CFS participants and healthy controls at baseline and at follow-up.
Reliability of Scores. We estimated the reliability of PROMIS F-SF raw sum scores by
calculating internal consistency coefficients (Cronbach’s alpha) and by calculating the amount of
measurement error in the T-score under IRT. It is generally recommended to use scales with
reliability coefficients of 0.70 and above for group-level analyses and 0.90 and above for
tracking individual patients [27,28]. These two coefficients are equivalent to a T-score standard
8

error of measurement (SEM) of 5.5 and 3.2, respectively. Previous research has shown IRTbased reliability statistics for the PROMIS F-SF scores which exceed 0.90 and T-score standard
errors < 3.2 for people with a wide range of fatigue scores [13]. We hypothesized that, consistent
with what has been observed in patients with other chronic diseases [29,30], the PROMIS F-SF
scores of the ME/CFS participants would have reliability estimates exceeding those
recommended for group-level comparisons (i.e. Cronbach’s alpha > 0.70 and the average
standard error for the T-score < 5.5).
DIF Analysis. DIF signifies that the item provides biased measurement across population
subgroups. Evidence of DIF occurs when the likelihoods of endorsing an item response category
are different across respondent subgroups that are matched on the underlying trait being
measured. Such a difference suggests that the variable used to define population subgroups, other
than the trait being measured, had an influence on the item responses.
We examined the possibility of DIF by sex and age for each PROMIS F-SF item using the Wald
test [31,32]. For age, we compared the measurement properties of PROMIS F-SF items across
three groups: 18-39, 40-59, and 60 or above. Patients ages 40-59 were used as the reference
group since ME/CFS is more prevalent in those ages [33,5]. This categorization allowed us to
have a sufficiently large number of participants in each group to examine DIF. For the Wald test,
a non-significant χ2 value indicates no detectable DIF. We used the Benjamin–Hochberg [34,35]
procedure to control for the multiple comparisons involved in checking DIF for each item by sex
and age. We hypothesized that there would be no evidence of DIF for PROMIS F-SF items in this
sample of ME/CFS participants.
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Known-Groups Validity. Known-groups validity of the PROMIS F-SF was evaluated by
comparing T-scores for groups that are known to differ in their fatigue levels. We hypothesized
that ME/CFS participants with higher levels of functional impairment would have PROMIS F-SF
scores indicating greater fatigue; and that ME/CFS participants would exhibit greater fatigue
than healthy controls. Initially, ME/CFS participants were classified into “low”, “medium”, and
“high” level of functional impairment, based on each of the following variables:
•

Hours spent in vertical activities per day. Participants reported the average time with feet on
the floor (e.g. sitting, standing or walking). Reported hours could be up to 15 and fewer hours
indicate more ME/CFS functional impairment. The median of vertical hours reported by
ME/CFS participants and healthy controls was 7 (range=0-15) and 14 (range=0-15),
respectively.

•

Hours spent in horizontal activities per day. Participants reported the average time with feet
up (e.g. resting in recliner with feet up, napping, sleeping in bed). Reported hours could be
up to 15 and more hours indicate more ME/CFS functional impairment. The median of
horizontal hours reported by ME/CFS participants and healthy controls was 14 (range=0-15),
and 8 (range=0-15), respectively.

•

Physical Health. Overall physical health was measured by Physical Component Summary
(PCS) T-scores of SF-36 (lower scores indicate more ME/CFS functional impairment).

Details about the variables for vertical/horizontal hours can be accessed in the supplement
materials [19]. For each variable, we used two tertiles to split data into three approximately
equal-sized groups of ME/CFS participants, so that each group has adequate sample size for
validity analyses. Since over 46% of ME/CFS participants were at the maximum of 15 hours of
horizontal activities per day, we were unable to divide participants into three equal-sized groups
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using that variable. Instead, we divided participants into two groups based on horizontal activity
level (15 hours vs. < 15 hours) to ensure adequate sample size in each group.
Analysis of variance (ANOVA) was used to examine mean differences in fatigue T-scores
among known-groups defined by the three aforementioned variables for ME/CFS participants,
and between ME/CFS participants and healthy controls. We used the Tukey–Kramer method
[36] for multiple comparison adjustment among known-groups. Known-groups validity was
considered acceptable when the difference in fatigue scores across groups was observed at a
significance level of 0.05. We reported means and standard deviations for the fatigue scores by
group along with effect sizes, and test statistics. Using the ANOVA results, we computed η2 by
dividing the sum of squares for the known-groups effect by the total sum of squares. We used
the η2 statistic as an effect-size measure and interpreted such effects as small (0.01), medium
(0.09), and large (0.25), following convention [37,38].
Responsiveness. Responsiveness represents an instrument’s ability to detect changes over time
when true changes exist. We hypothesized that ME/CFS participants with “improved”, “stable”,
and “worsened” health would show a significant decrease, no significant changes, and a
significant increase in their PROMIS F-SF fatigue scores, respectively. We initially categorized
ME/CFS participants into three groups of “improved”, “stable,” and “worsened” using the
following measures of functional status:
•

Hours vertical. Change in number of hours of vertical activities per day from baseline to
follow-up: improved= “≥ one-hour increase in vertical activities”; stable= “within one-hour”;
worsened= “≥ one-hour decrease in vertical activities”
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•

Hours horizontal. Change in number of hours of horizontal activities per day from baseline to
follow-up: improved= “≥ one-hour increase in horizontal activities”; stable= “within onehour”; worsened= “≥ one-hour decrease in horizontal activities”

•

Physical health. Change in SF-36 PCS T-score from baseline to follow-up: improved =
“score increase > 5”; stable = “score increase or decrease ≤ 5”; worsened = “score decrease >
5”

For vertical/horizontal activities, there was no established cutoff for the minimal clinically
important difference (MCID). Because time spent in these activities was reported in integer
hours, we considered patients as stable if the change from baseline to follow-up was within an
hour. For SF-36 PCS T-scores, we identified a change of 5 as the MCID and considered patients
as stable if the change from baseline to follow-up was ≤5. Previously published MCIDs of SF-36
PCS across different studies range from 2.5 to about 7 [39-41]. To our knowledge, the MCID of
SF-36 PCS has not been studied for ME/CFS. Therefore, we used the half standard deviation
approach [42] and chose an MCID of 5 for assessing the responsiveness among ME/CFS
participants.
About 50% of ME/CFS participants reported the worst possible functional status at baseline on
any of the 3 aforementioned criterion variables. Among those participants, it was impossible to
distinguish those whose functional status declined from those whose functional status remained
stable: some of the participants who appeared to be stable (e.g., reporting 15 hours of horizontal
activities at both baseline and follow-up) might have experienced a worsening in their
functioning that was undetectable. Thus, we combined the “stable” and “worsened” groups into
a group of “not improved.”
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We used ANOVA to examine if changes in fatigue scores significantly differed among groups
that we defined as “improved,” “stable”, and “worsened” or between the “improved” and “not
improved” groups. We report means and standard deviations of fatigue change scores for each
group. We calculated Guyatt's responsiveness statistic (GRS) as an effect size comparing the
“improved” groups to the “stable,” “worsened,” or “not improved” groups. The GRS is defined
as the mean change in fatigue scores for the target group (i.e., “improved”) divided by the
standard deviation of the comparison group (e.g., “not improved”) [43] and is interpreted as
small (≥0.2 and <0.5), medium (≥0.5 and <0.8), and large (≥0.8) [37].
Results
The majority of ME/CFS participants were female (74.3%), white (92.5%), and not currently
working (69.6%) (Table 1). Their mean age was 48.1 years with the illness duration of 13.5
years.
------------------------------------Insert Table 1 about Here
-------------------------------------Item Descriptive Statistics
Table 2 summarizes the item responses of ME/CFS participants for each PROMIS F-SF item.
The percentage of participants responding “5” (representing the highest level of fatigue) ranged
from 6.4% to 72.9% across the seven items, indicating that these items cover a wide range of
fatigue level.

13

Table 2 also shows the number and percentage of ME/CFS participants who selected the
greatest-fatigue category for all items in the measure or selected the least-fatigue category for all
items in the measure, along with the raw sum score means and standard deviations. Only a very
small proportion of participants were at the greatest fatigue score (1.8%) and almost no
participants were at the lowest fatigue score (0.4%), suggesting that floor/ceiling effect was not a
concern.
------------------------------------Insert Table 2 about Here
-------------------------------------When using the IRT approach, the mean T-score of the PROMIS F-SF at 68.6 in ME/CFS
participants, was nearly two standard deviations above the national norm, supporting the validity
of the PROMIS F-SF for ME/CFS.
Reliability
The PROMIS F-SF showed high internal consistency (Cronbach’s α = 0.84) among ME/CFS
participants. When using the IRT approach, we found the average standard error of fatigue Tscore was 2.9 and well below the hypothesized threshold of 5.5 that corresponds to a reliability
of 0.7, indicating high precision of the PROMIS F-SF scores for ME/CFS.
DIF
Table 3 shows results from the Wald test for DIF detection by sex and by age. Before using the
Benjamini–Hochberg correction for multiplicity, one PROMIS F-SF item (“think clearly”)
showed possible DIF by sex, with a p value < 0.05. However, after correction for multiplicity,
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none of the items exhibited significant DIF by sex. None of the items exhibited significant DIF
by age, even before correcting for multiplicity.
------------------------------------Insert Table 3 about Here
-------------------------------------Known-Groups Validity
Results in Table 4 show that the omnibus hypothesis of no differences among known groups was
rejected with p < 0.0001, providing supportive evidence for the validity of the PROMIS F-SF in
ME/CFS. Furthermore, we found significant differences for all pairwise comparisons between
groups with a monotonic increase in mean scores across low, medium, and high functional
impairment groups of ME/CFS participants. ME/CFS participants had significantly higher mean
scores than healthy controls. Effect sizes, η2, were medium for known-groups defined by vertical
activities and horizontal activities, and large for known-groups defined by SF-36 PCS scores and
when comparing ME/CFS participants to healthy controls.
------------------------------------Insert Table 4 about Here
-------------------------------------Responsiveness
The omnibus hypothesis of no differences among groups of ME/CFS participants defined by
whether they improved, remained stable, or worsened was rejected with p < 0.05. In pairwise
comparisons between the groups, however, no significant difference was found between the
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“stable” and “worsened” groups. This is probably due to: (1) the inability to differentiate
between “stable” and “worsened” for a large proportion of participants who remained at the
maximum hours of horizontal activity from baseline to follow-up, and (2) the small sample size
for the “worsened” group based on SF-36 PCS change score (11%, n=43). Due to space
limitations, detailed results comparing the “improved”, “stable”, and “worsened” groups are
omitted here.
In Table 5, we show the results comparing change for “improved” vs. “not improved” groups.
Decreases in fatigue scores were significantly larger in the “improved” group than in the “not
improved” group (p < 0.05). Guyatt’s responsiveness statistics were small to medium. These
results provide supportive evidence of responsiveness for PROMIS F-SF in ME/CFS.
------------------------------------Insert Table 5 about Here
-------------------------------------Discussion
The PROMIS F-SF showed strong reliability and validity to assess fatigue outcome for ME/CFS
participants by demonstrating good internal consistency, minimal to almost no floor/ceiling
effects at the total score level, good known-groups validity with medium-to-large effect sizes,
and acceptable responsiveness to change with small-to-medium effect sizes. Consistent with our
hypotheses, the PROMIS F-SF had internal consistency reliability well above the acceptable
threshold of 0.70. As expected, the fatigue T-score had a monotonic increase across ME/CFS
participant groups with low, medium, and high functional impairment, and ME/CFS participants
had significantly higher fatigue scores than healthy controls. Moreover, as expected, ME/CFS
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participants who experienced improvement in their functional status over time showed a
significant decrease in their PROMIS F-SF fatigue scores compared with those experiencing no
improvement. No DIF was detected by age or sex, suggesting that all items provide unbiased
measurement across these population subgroups. All findings were in support of qualifying the
PROMIS F-SF as a DDT for use in clinical trials of therapy for ME/CFS. To meet FDA’s
requirement for COA qualification, we will further examine the content validity and test-retest
reliability of the PROMIS F-SF in future research.
Since ME/CFS participants commonly have much higher fatigue levels than the general US
population, we originally expected that quite a few participants, although no more than 15%,
would select the greatest-fatigue category for all items in the PROMIS F-SF. However, results
suggest that the PROMIS F-SF covered a broad range of fatigue levels and exhibited minimal
restriction on the measurement range within this high-fatigue patient population. The PROMIS
F-SF is a generic (i.e., not condition-specific) measure that has been tested in various patient
populations (e.g., multiple sclerosis, fibromyalgia, sickle cell disease, cardiometabolic risk,
pregnancy) [44,45]. It provides a good opportunity for researchers and clinicians to use a single
instrument that allows comparisons within ME/CFS participants with varying levels of
functioning impairment as well as comparisons of ME/CFS participants and patients with other
fatiguing illnesses.
There are a few limitations to our research which should be considered when interpreting results
from this study, and some of them suggest future research directions. First, all participants from
the MCAM study were receiving tertiary care, thus did not match the composition of the broad
U.S. ME/CFS population. On the other hand, ME/CFS participants receiving tertiary care from a
clinic are likely to be the population recruited for clinical trials of therapy in ME/CFS. Although
17

we believe our large sample size recruited from seven clinics across seven states provides a
useful population for validity analysis, future studies using more diverse samples should be
conducted to evaluate the stability of parameter estimates.
Second, the known-group validity analysis for responsiveness to change was compromised by
restricted range of measurement of functional status. That is, a large proportion of ME/CFS
participants began the study with the worse possible functional impairment. For such
participants, we were unable to distinguish those who were truly stable from those who
experienced an undetectable worsening in functional status. Other ME/CFS severity indicators
with minimal floor/ceiling effects need to be identified to better define participants with stable
functional status over time. Such indicators would facilitate further analyses on responsiveness
and the evaluation of test-retest reliability among stable participants.
Third, some researchers may argue that, compared to a condition-specific measure, the generic
PROMIS F-SF does not include items reflecting unique fatigue symptoms in ME/CFS, thus
reducing its content validity in this patient population. Patients with chronic fatigue did take part
in focus groups conducted to evaluate the content of the PROMIS Fatigue measure, but the data
from those focus groups was not tagged by diagnosis, so it is not possible to distinguish the
comments of participants with ME/CFS from those of participants with other chronic conditions
[46]. Cognitive debriefing studies of the PROMIS F-SF could be conducted with ME/CFS
patients to obtain additional content validity evidence for those items in that specific patient
population.
Despite these limitations, the results of this study contribute unique information about the
reliability and validity of the PROMIS F-SF in general and when used in patients with ME/CFS
18

in particular. This information will be useful to those selecting measures of fatigue for ME/CFS
going forward.
Conclusion
Study findings support the reliability and validity of PROMIS F-SF as a measure of fatigue for
ME/CFS and lend support to the drug development tool submission for qualifying this measure
to evaluate therapeutic effect in ME/CFS clinical trials, which is an important step toward
developing FDA-approved treatment for this debilitating illness.
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Table 1. Sample characteristics at baseline
ME/CFS

Healthy Control

(n=549)a

(n=304) a

n

%

n

%

408

74.3

200

65.8

White

508

92.5

176

57.9

Black/African American

11

2.0

18

5.9

All others

25

4.6

76

25.0

Married/committed

293

53.4

151

49.7

Previously married

92

16.8

54

17.8

Never married

150

27.3

91

29.9

Full-time

84

15.3

162

53.3

Part-time

60

10.9

54

17.8

Not working

382

69.6

77

25.3

Mean

SDb

Mean

SDb

Age, years

48.1

12.8

43.8

14.9

Illness duration, years

13.5

9.7

NA

NA

Female sex
Race

Marital status

Employment

a

Frequency numbers do not add up to the total number of participants and percentages do not add up to
100% because of missing data.
b

SD = Standard Deviation
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Table 2. Item-level descriptive statistics and measure-level raw sum score distributions for
PROMIS F-SF, based on ME/CFS participant data at baseline (n=549) from the MCAM study
Item

SDa

Response of "1"

Response of "5"

(Lowest Level of

(Highest Level of

Fatigue)

Fatigue)

n

%

n

%

PROMIS1: feel tired

4.54

0.68

3

0.5

339

61.7

PROMIS2: extreme exhaustion

3.70

0.93

13

2.4

99

18.0

PROMIS3: out of energy

4.16

0.79

4

0.7

192

35.0

PROMIS4: limit work

4.39

0.84

7

1.3

303

55.2

PROMIS5: think clearly

3.60

0.87

15

2.7

58

10.6

PROMIS6: bath/shower

2.98

1.13

75

13.7

35

6.4

PROMIS7: strenuous exercise

4.51

1.00

23

4.2

400

72.9

PROMIS F-SF (raw sum score 7-35)
a

Mean

27.6

4.7

SD = Standard Deviation
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Participants at the

Participants at the

Lowest Possible

Highest Possible

Score of Fatigue

Score of Fatigue

2

0.4

10

1.8

Table 3. Differential item functioning (DIF) statistics by sex and age, based on baseline ME/CFS
participant data (n=549) from the MCAM study
Label

DIF by Sex

DIF by Age

DIF by Age

Male vs Female

18-39 vs. 40-59

60+ vs. 40-59

χ2

df

p

χ2

df

p

χ2

df

p

PROMIS1: feel tired

1.9

5

0.860

4.1

4

0.394

4.5

4

0.344

PROMIS2: extreme exhaustion

1.7

5

0.889

1.1

5

0.958

5.3

5

0.379

PROMIS3: out of energy

1.5

5

0.914

0.4

4

0.985

4.8

4

0.308

PROMIS4: limit work

3.1

5

0.688

1.2

4

0.882

7.1

4

0.133

PROMIS5: think clearly

14.9

5

0.011

5.4

5

0.365

2.8

5

0.730

PROMIS6: bath/shower

6.9

5

0.233

6.3

5

0.283

3.8

5

0.580

PROMIS7: strenuous exercise

8.7

5

0.121

9.6

5

0.087

6.7

5

0.247

PROMIS F-SF
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Table 4. Mean fatigue scores by three indicators of functional impairment level as well as
between ME/CFS participants and healthy controls from the MCAM study
Known Groups

n

PROMIS F-SF
Mean

SD a

F

η2 b

ME/CFS functional impairment level defined by hours of vertical activities per day c
Low (≥ 10 hours)

190

65.5

8.4

Medium (≥ 5 and < 10 hours)

181

68.9

5.9

High (< 5 hours)

164

71.5

5.7

34.4

0.115

ME/CFS functional impairment level defined by hours of horizontal activities per day d
Lower (< 15 hours)

286

66.6

8.0

Higher (15 hours)

250

70.7

5.5

45.8

0.079

88.8

0.247

1915.0

0.692

ME/CFS functional impairment level defined by SF-36 PCS scoree
Low (T-score ≥ 28.78)

180

63.9

8.0

Medium (20.49 ≤ T-score < 28.78)

184

69.3

5.6

High (T-score < 20.49)

179

72.7

4.8

ME/CFS participants

549

68.6

7.2

Healthy controls

304

44.8

8.2

ME/CFS participants vs. healthy controlsd

a

SD = Standard Deviation
η2 is an effect size measure and was computed by dividing the sum of squares for the known-groups
effect by the total sum of squares.
c
Overall differences among the three groups were significant at p < 0.0001; group differences of low vs.
medium and low vs. high functional impairment were significant at p < 0.0001; group differences of
medium vs. high functional impairment were significant at p < 0.01.
d
Differences were significant at p < 0.0001.
e
Group differences, overall and between any two functional impairment levels, were significant at p <
0.0001.
b
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Table 5. Mean changes in fatigue scores between “improved” and “not improved” groups
defined by three anchor measures from the MCAM study
Change Status

n

PROMIS F-SF
Guyatt's
Responsiveness
Mean

SDa

F

p

Statistic

Change in hours of vertical activities per day, from baseline to follow-up
Improved

135

-1.73

5.96

Not Improved

240

0.04

5.57

8.3

0.004

-0.318

Change in hours of horizontal activities per day, from baseline to follow-up
Improved

100

-1.72

6.52

Not Improved

275

-0.20

5.42

5.1

0.024

-0.280

Change in SF-36 PCS score, from baseline to follow-up

a

Improved

98

-2.70

6.30

Not Improved

276

0.19

5.41

19.0

<.0001

SD= Standard Deviation
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-0.536

